PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 268 filers reported holding PACIRA PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 3.49 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $411,000 | +6.2% | 7,724 | +16.5% | 0.02% | +31.6% |
| Q2 2022 | $387,000 | -43.9% | 6,631 | -42.2% | 0.02% | -26.9% |
| Q4 2021 | $690,000 | +20.0% | 11,465 | +11.7% | 0.03% | -13.3% |
| Q3 2021 | $575,000 | -45.9% | 10,262 | -41.4% | 0.03% | -34.8% |
| Q2 2021 | $1,062,000 | +9.7% | 17,499 | +8.2% | 0.05% | -42.5% |
| Q4 2020 | $968,000 | +372.2% | 16,173 | +373.7% | 0.08% | +263.6% |
| Q3 2020 | $205,000 | -19.9% | 3,414 | -29.9% | 0.02% | -48.8% |
| Q2 2020 | $256,000 | -51.2% | 4,870 | -58.0% | 0.04% | 0.0% |
| Q4 2019 | $525,000 | -47.8% | 11,599 | -56.1% | 0.04% | -29.5% |
| Q3 2019 | $1,006,000 | -0.9% | 26,437 | +13.3% | 0.06% | -30.7% |
| Q2 2019 | $1,015,000 | +53.8% | 23,342 | +34.6% | 0.09% | -12.0% |
| Q1 2019 | $660,000 | +72.3% | 17,340 | +94.8% | 0.10% | -12.3% |
| Q4 2018 | $383,000 | – | 8,900 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |